Lutetium 177 PMSA Therapy for Metastatic Castrate Resistant Prostate Cancer: A Zambian Case Report

Abstract

Introduction: Prostate cancer is the most prevalent noncutaneous cancer in men, with a lifetime risk of 12.5%. Globally, it ranks as the second most common incident cancer in men, following lung cancer, and stands as the sixth leading cause of cancer mortality in men. International incidence and death rates vary significantly, with higher mortality rates observed in the Caribbean, parts of South America, and sub-Saharan Africa. Materials and Methods: We present the case of a 63-year-old black Zambian male patient diagnosed with high-risk prostate cancer. The patient was first seen at Cancer Diseases Hospital (CDH) in Zambia in October 2016 with a Gleason score (GS) of 8 (4+4) and an initial prostate-specific antigen (PSA) level of 93.49 ng/ml. H. Results: The preliminary findings of this case underscore the potential role of Lutetium 177 PSMA therapy in managing patients with metastatic castration-resistant prostate cancer (mCRPC) in Zambia. Conclusion: This case highlights the importance of advocating for policies and initiatives that aim to increase the accessibility of advanced prostate cancer treatments in Zambia, especially with the increasing burden of prostate cancer in regions like Africa. Urgent measures are needed to improve access to advanced therapeutic options such as PSMA-based therapies.